CR20210267A - Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) para el tratamiento de trastornos metabólicos - Google Patents
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) para el tratamiento de trastornos metabólicosInfo
- Publication number
- CR20210267A CR20210267A CR20210267A CR20210267A CR20210267A CR 20210267 A CR20210267 A CR 20210267A CR 20210267 A CR20210267 A CR 20210267A CR 20210267 A CR20210267 A CR 20210267A CR 20210267 A CR20210267 A CR 20210267A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sub
- pcsk9
- inhibitors
- treatment
- metabolic disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
Abstract
La invención se refiere a inhibidores de PCSK9 de utilidad en el tratamiento del metabolismo de los lípidos del colesterol y otras enfermedades en las que PCSK9 interviene, que tienen la fórmula (I): o una sal, hidrato, solvato, profármaco, estereoisómero, N-óxido o tautómero farmacéuticamente aceptable de los mismos, en donde R<sub>1</sub>, R<sub>1</sub>, R<sub>1</sub>, R<sub>1</sub>, R<sub>1</sub>, R<sub>1</sub>, R<sub>1</sub>, R<sub>1</sub>, R<sub>1</sub>, X<sub>1</sub>, X<sub>2</sub>, y X<sub>3</sub> están descriptos en la presente
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862772030P | 2018-11-27 | 2018-11-27 | |
US201962924828P | 2019-10-23 | 2019-10-23 | |
PCT/IB2019/060201 WO2020110009A1 (en) | 2018-11-27 | 2019-11-26 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210267A true CR20210267A (es) | 2021-08-16 |
Family
ID=68808460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210267A CR20210267A (es) | 2018-11-27 | 2019-11-26 | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) para el tratamiento de trastornos metabólicos |
Country Status (24)
Country | Link |
---|---|
US (2) | US11026993B2 (es) |
EP (1) | EP3887365A1 (es) |
JP (1) | JP2022507957A (es) |
KR (1) | KR20210096154A (es) |
CN (1) | CN113166114A (es) |
AU (1) | AU2019387294B2 (es) |
BR (1) | BR112021009857A2 (es) |
CA (1) | CA3115960A1 (es) |
CL (1) | CL2021001365A1 (es) |
CO (1) | CO2021006895A2 (es) |
CR (1) | CR20210267A (es) |
CU (1) | CU20210043A7 (es) |
DO (1) | DOP2021000100A (es) |
EC (1) | ECSP21036194A (es) |
IL (1) | IL283374A (es) |
JO (1) | JOP20210120A1 (es) |
MA (1) | MA54284A (es) |
MX (1) | MX2021006069A (es) |
PE (1) | PE20211658A1 (es) |
PH (1) | PH12021551049A1 (es) |
SG (1) | SG11202103807WA (es) |
TW (1) | TW202038990A (es) |
UY (1) | UY38485A (es) |
WO (1) | WO2020110009A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11882610B2 (en) * | 2020-08-13 | 2024-01-23 | Qualcomm Incorporated | Establishing connections using multiple subscriber identity modules via a single communication link |
CN114163343A (zh) * | 2021-12-10 | 2022-03-11 | 许昌学院 | 含氟氨基酸及衍生物含氟多肽的制备方法以及应用 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
US4818541A (en) | 1987-08-19 | 1989-04-04 | Schering Corporation | Transdermal delivery of enantiomers of phenylpropanolamine |
DE69129226T2 (de) | 1990-01-24 | 1998-07-30 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
IT1291776B1 (it) | 1997-02-07 | 1999-01-21 | Menarini Ricerche Spa | Composti monociclici a quattro residui bifunzionali, aventi azione nk-2 antagonista |
IT1304888B1 (it) | 1998-08-05 | 2001-04-05 | Menarini Ricerche Spa | Composti monociclici ad azione nk-2 antagonista e formulazioni che licontengono |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
IT1307809B1 (it) * | 1999-10-21 | 2001-11-19 | Menarini Ricerche Spa | Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono. |
IL152081A0 (en) | 2000-04-12 | 2003-05-29 | Novartis Ag | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
EP1297826A1 (en) | 2001-09-27 | 2003-04-02 | Menarini Ricerche S.p.A. | Nasal pharmaceutical compositions containing a NK-2 antagonist |
TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
TW200407310A (en) | 2002-06-07 | 2004-05-16 | Glaxo Group Ltd | Compounds |
ATE335744T1 (de) | 2002-08-07 | 2006-09-15 | Novartis Pharma Gmbh | Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen |
US7223866B2 (en) | 2002-11-18 | 2007-05-29 | Novartis Ag | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases |
PE20050157A1 (es) | 2003-05-20 | 2005-05-17 | Novartis Ag | Derivados de n-acil nitrogeno heterociclicos como ligandos del receptor activador del proliferador de peroxisoma (ppar) |
ATE490241T1 (de) | 2004-05-28 | 2010-12-15 | Novartis Ag | Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren |
CA2568165A1 (en) | 2004-05-28 | 2005-12-15 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
US20080076784A1 (en) | 2004-05-28 | 2008-03-27 | Peter Herold | Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors |
AR049711A1 (es) | 2004-07-09 | 2006-08-30 | Speedel Experimenta Ag | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso |
TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
AR056888A1 (es) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
CA2647819C (en) | 2006-03-31 | 2012-12-11 | Novartis Ag | Phenylcyclohexyl derivatives as dgat1 inhibitors |
US20090156875A1 (en) | 2006-04-04 | 2009-06-18 | Takafumi Tomioka | Methane separation method, methane separation apparatus, and methane utilization system |
TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
WO2008027284A1 (en) | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
WO2008076862A2 (en) | 2006-12-18 | 2008-06-26 | Novartis Ag | 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors |
US8143278B2 (en) | 2006-12-18 | 2012-03-27 | Novartis Ag | Organic compounds |
EA200900811A1 (ru) | 2006-12-18 | 2009-12-30 | Новартис Аг | Имидазолы в качестве ингибиторов альдостеронсинтазы |
AR066691A1 (es) | 2007-03-29 | 2009-09-09 | Speedel Experimenta Ag | Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas. |
TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
US7834041B2 (en) | 2007-09-07 | 2010-11-16 | Theravance, Inc. | Dual-acting antihypertensive agents |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
JP2011518884A (ja) | 2008-04-29 | 2011-06-30 | セラヴァンス, インコーポレーテッド | 二重活性抗高血圧剤 |
AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
PT2358737T (pt) | 2008-10-23 | 2017-06-12 | Steba Biotech S A | Peptidomiméticos que contêm rgd e utilizações dos mesmos |
ES2459468T3 (es) | 2009-05-15 | 2014-05-09 | Novartis Ag | Arilpiridinas como inhibidores de aldosterona sintasa |
CN103896796B (zh) | 2009-05-28 | 2016-04-27 | 诺华股份有限公司 | 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物 |
JP5466759B2 (ja) | 2009-05-28 | 2014-04-09 | ノバルティス アーゲー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
BR112012007241A2 (pt) | 2009-10-01 | 2019-09-24 | Cadila Healthcare Ltd Soc Indiana | compostos , composição farmacêutica, método para tratar desordens, uso dos compostos, medicamento, método para selecionar inibidores com pequenas moléculas de pcsk9 e pequenas moléculas |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
NZ599774A (en) | 2009-11-23 | 2014-11-28 | Palatin Technologies Inc | Melanocortin-1 receptor-specific cyclic peptides |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
US8586536B2 (en) | 2010-12-15 | 2013-11-19 | Theravance, Inc. | Neprilysin inhibitors |
RU2604522C2 (ru) | 2011-02-17 | 2016-12-10 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи,ЭлЭлСи | Замещенные аминомасляные производные в качестве ингибиторов неприлизина |
ES2642883T3 (es) | 2011-05-31 | 2017-11-20 | Theravance Biopharma R&D Ip, Llc | Inhibidores de neprilisina |
US8513244B2 (en) | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
MX356260B (es) | 2012-06-08 | 2018-05-21 | Theravance Biopharma R&D Ip Llc | Inhibidores de la neprilisina. |
DE102012014480A1 (de) | 2012-07-21 | 2014-01-23 | Daimler Ag | Aufbau eines Innendekors |
LT2882716T (lt) | 2012-08-08 | 2017-02-10 | Theravance Biopharma R&D Ip, Llc | Neprilizino inhibitoriai |
US20150218212A1 (en) | 2012-08-21 | 2015-08-06 | Fluorinov Pharma Inc. | Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors |
NZ710574A (en) | 2013-02-14 | 2017-11-24 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
SI2964616T1 (sl) | 2013-03-05 | 2017-08-31 | Theravance Biopharma R&D Ip, Llc | Zaviralci neprilizina |
AU2014237198A1 (en) | 2013-03-15 | 2015-11-05 | Shifa Biomedical Corporation | Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases |
AU2015211041B2 (en) | 2014-01-30 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors |
KR20160113291A (ko) | 2014-01-30 | 2016-09-28 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 네프리리신 저해제 |
TW201823222A (zh) * | 2016-12-23 | 2018-07-01 | 財團法人生物技術開發中心 | 化合物、醫藥組成物及其用途 |
-
2019
- 2019-11-22 UY UY0001038485A patent/UY38485A/es unknown
- 2019-11-25 TW TW108142721A patent/TW202038990A/zh unknown
- 2019-11-26 KR KR1020217019281A patent/KR20210096154A/ko unknown
- 2019-11-26 CN CN201980076002.XA patent/CN113166114A/zh active Pending
- 2019-11-26 MX MX2021006069A patent/MX2021006069A/es unknown
- 2019-11-26 CR CR20210267A patent/CR20210267A/es unknown
- 2019-11-26 JO JOP/2021/0120A patent/JOP20210120A1/ar unknown
- 2019-11-26 WO PCT/IB2019/060201 patent/WO2020110009A1/en unknown
- 2019-11-26 CU CU2021000043A patent/CU20210043A7/es unknown
- 2019-11-26 JP JP2021529266A patent/JP2022507957A/ja active Pending
- 2019-11-26 SG SG11202103807WA patent/SG11202103807WA/en unknown
- 2019-11-26 US US16/695,843 patent/US11026993B2/en active Active
- 2019-11-26 AU AU2019387294A patent/AU2019387294B2/en active Active
- 2019-11-26 BR BR112021009857-7A patent/BR112021009857A2/pt not_active Application Discontinuation
- 2019-11-26 EP EP19816905.4A patent/EP3887365A1/en active Pending
- 2019-11-26 MA MA054284A patent/MA54284A/fr unknown
- 2019-11-26 CA CA3115960A patent/CA3115960A1/en active Pending
- 2019-11-26 PE PE2021000749A patent/PE20211658A1/es unknown
-
2021
- 2021-03-12 US US17/200,471 patent/US11813306B2/en active Active
- 2021-05-06 PH PH12021551049A patent/PH12021551049A1/en unknown
- 2021-05-21 EC ECSENADI202136194A patent/ECSP21036194A/es unknown
- 2021-05-23 IL IL283374A patent/IL283374A/en unknown
- 2021-05-24 DO DO2021000100A patent/DOP2021000100A/es unknown
- 2021-05-25 CO CONC2021/0006895A patent/CO2021006895A2/es unknown
- 2021-05-25 CL CL2021001365A patent/CL2021001365A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3115960A1 (en) | 2020-06-04 |
PE20211658A1 (es) | 2021-08-24 |
US20200164024A1 (en) | 2020-05-28 |
JP2022507957A (ja) | 2022-01-18 |
MX2021006069A (es) | 2021-07-06 |
US11026993B2 (en) | 2021-06-08 |
CO2021006895A2 (es) | 2021-06-10 |
AU2019387294A1 (en) | 2021-05-13 |
CN113166114A (zh) | 2021-07-23 |
US20210252103A1 (en) | 2021-08-19 |
EP3887365A1 (en) | 2021-10-06 |
PH12021551049A1 (en) | 2021-12-06 |
US11813306B2 (en) | 2023-11-14 |
IL283374A (en) | 2021-07-29 |
WO2020110009A1 (en) | 2020-06-04 |
JOP20210120A1 (ar) | 2023-01-30 |
BR112021009857A2 (pt) | 2021-08-17 |
AU2019387294B2 (en) | 2022-09-08 |
CL2021001365A1 (es) | 2022-01-14 |
KR20210096154A (ko) | 2021-08-04 |
ECSP21036194A (es) | 2021-06-30 |
SG11202103807WA (en) | 2021-06-29 |
DOP2021000100A (es) | 2021-06-30 |
TW202038990A (zh) | 2020-11-01 |
CU20210043A7 (es) | 2022-01-13 |
UY38485A (es) | 2020-06-30 |
MA54284A (fr) | 2022-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019013574A (es) | Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio. | |
MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
NZ702093A (en) | Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9) | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
MX2022000244A (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas. | |
HK1133596A1 (en) | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme | |
EA033689B9 (ru) | Ингибиторы g12c kras | |
HK1116161A1 (en) | Substituted amide derivatives as protein kinase inhibitors | |
PH12021551049A1 (en) | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders | |
EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
NZ710574A (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors | |
MX2015012111A (es) | Moduladores de ship1 y métodos relacionados con éstos. | |
MY165902A (en) | Substituted pyridine derivatives as fabi inhibitors | |
PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). | |
UA103329C2 (ru) | Соли соединений-ингибиторов вич | |
MX2022012998A (es) | Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2 -(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-aci do ciclo-propilpropanoico y su forma cristalina para uso como principio activo farmaceutico. | |
MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
MX2018011592A (es) | Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo. | |
WO2014144836A3 (en) | Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors | |
PH12017501832A1 (en) | Stabilized pharmaceutical composition | |
MX2022000154A (es) | Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos. | |
MY198008A (en) | Crystal of benzofuran derivative free base and preparation method | |
EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида |